Previous close | 79.83 |
Open | 79.77 |
Bid | 0.00 x 1200 |
Ask | 81.00 x 800 |
Day's range | 79.77 - 80.86 |
52-week range | 52.83 - 80.86 |
Volume | 7,955,621 |
Avg. volume | 12,938,998 |
Market cap | 210.033B |
Beta (3Y monthly) | 0.38 |
PE ratio (TTM) | 34.81 |
EPS (TTM) | 2.32 |
Earnings date | 30 Apr 2019 |
Forward dividend & yield | 2.20 (2.78%) |
Ex-dividend date | 2019-03-14 |
1y target est | 83.02 |
Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.
Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
The index endured a holiday-shortened but volatile week.
NEW YORK, Feb. 21, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Immune Design Corp. (“Immune Design”.
Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Marks First Application for KEYTRUDA in SCLC
Merck , known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-240 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus best supportive care, for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy, did not meet its co-primary endpoints of overall survival and progression-free survival ...
Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.
A drug that disappointed in 2018 will get an unexpected dance at the big ball.
U.S. Approval Based on Significant Recurrence-Free Survival Benefit Demonstrated with KEYTRUDA in Phase 3 EORTC1325/KEYNOTE-054 Trial
Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday. Nearly 90 percent of patients who received the combination therapy were still alive after 12 months compared with about 78 percent of patients who were alive after a year when treated with the older drug Sutent, data showed. Merck on Monday released interim data from the trial, saying the combination reduced the risk of death by 47 percent compared with Sutent.
Results from Phase 3 KEYNOTE-426 Study Presented Today at the 2019 Genitourinary Cancers Symposium and Published in the New England Journal of Medicine Also Showed Risk o
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth driversOn its fourth-quarter earnings conference call, Merck & Co. (MRK) highlighted its oncology, vaccines, hospital and specialty care, and animal
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Dividend projectionsMerck & Co. (MRK) and GlaxoSmithKline (GSK) reported dividends per share of $1.99 and $2.08, respectively, in 2018.Analysts expect
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Expenses guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for a low- to mid-single-digit YoY (year-over-year) rise
Application Based on Overall Survival and Progression-Free Survival Data from Phase 3 KEYNOTE-426 Trial
Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,202,363 ("the ‘363 patent") on Feb. 12, 2019, which is directed to CERC‑301, an oral, NR2B-specific, NMDA receptor antagonist. CERC-301 is a selective NR2B-specific NMDA receptor antagonist with a unique mechanism of action tested in 375 subjects to date. CERC-301 is being developed for the treatment of Neurogenic Orthostatic Hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy and Pure Autonomic Failure.
Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.